Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 06 2025 - 8:00AM
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical
company focused on the development and commercialization of
therapeutics for central nervous system (CNS) disorders, today
announced that Sharon Mates, Ph.D., Chief Executive Officer and
Chairman, is scheduled to present at the 43rd Annual J.P. Morgan
Healthcare Conference on Monday, January 13, 2025 at 11:15 a.m. PT
in San Francisco, CA.
The live and archived webcast can be accessed under "Events
& Presentations" in the Investors section of the Company's
website at www.intracellulartherapies.com. Please log in
approximately 5-10 minutes prior to the event to register and to
download and install any necessary software.
About Intra-Cellular
TherapiesIntra-Cellular Therapies is a biopharmaceutical
company founded on Nobel prize-winning research that allows us to
understand how therapies affect the inner-workings of cells in the
body. The company leverages this intracellular approach to develop
innovative treatments for people living with complex psychiatric
and neurologic diseases. For more information, please visit
www.intracellulartherapies.com.
Contact:Intra-Cellular Therapies, Inc.Juan
Sanchez, M.D.Vice President, Corporate Communications and Investor
Relations646-440-9333
Burns McClellan, Inc.Cameron Radinovic
cradinovic@burnsmc.com 646-930-4406
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Dec 2024 to Jan 2025
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Jan 2024 to Jan 2025